Last updated: September 7, 2026
Executive summary: Lasmiditan succinate, marketed by Eli Lilly as Reyvow, entered the U.S. market in February 2020 as the first approved “ditan” for acute migraine treatment. Its commercial trajectory has been constrained by an eight-hour driving restriction, central nervous system adverse effects, limited physician adoption relative to gepants, and intense competition from established triptans and newer products such as Nurtec ODT, Ubrelvy, Zavzpret, and Qulipta. Lilly does not disclose Reyvow revenue separately in its public financial reports, indicating that sales are not material to the company’s reported product portfolio. U.S. market exclusivity based on new chemical entity status expired in October 2024, while patent protection may extend beyond that date.
Lasmiditan Succinate Market Dynamics, Financial Trajectory, Patents, and Generic Risk
What is the regulatory status of lasmiditan succinate?
Lasmiditan succinate is the succinate salt of lasmiditan, a selective serotonin 5-HT1F receptor agonist. Reyvow is approved for the acute treatment of migraine with or without aura in adults. It is not approved for preventive migraine treatment.
The FDA approved Reyvow on Oct. 11, 2019. Lilly launched the product in February 2020, shortly before the COVID-19 pandemic disrupted new-product prescribing, patient visits, and pharmaceutical sales activity [1].
| Regulatory attribute |
Lasmiditan succinate |
| Brand name |
Reyvow |
| Sponsor |
Eli Lilly and Company |
| Active ingredient |
Lasmiditan |
| Dosage form |
Oral tablet |
| Strengths |
50 mg and 100 mg |
| FDA indication |
Acute treatment of migraine in adults |
| Preventive indication |
No |
| FDA approval date |
Oct. 11, 2019 |
| U.S. launch |
February 2020 |
| Drug class |
Selective 5-HT1F receptor agonist, or ditan |
| Controlled-substance status |
DEA scheduling was removed in 2020 |
| Key label restriction |
Patients should not drive or operate machinery for at least eight hours after dosing |
The FDA label states that lasmiditan can cause dizziness, somnolence, fatigue, paresthesia, and sedation. The eight-hour driving restriction is commercially significant because it limits use by patients who need to remain functionally active after treating a migraine [2].
How does lasmiditan work, and what differentiates it from triptans?
Lasmiditan activates 5-HT1F receptors without the vasoconstrictive activity associated with 5-HT1B/1D agonists such as sumatriptan and rizatriptan. That mechanism was intended to address migraine patients who cannot use triptans because of cardiovascular disease or vascular risk.
The differentiation is clinically clear but commercially incomplete:
| Product category |
Representative products |
Main advantage |
Main limitation |
| Triptans |
Imitrex, Maxalt, Relpax |
Low cost and extensive physician familiarity |
Vasoconstriction and cardiovascular restrictions |
| Ditans |
Reyvow |
No triptan-like vasoconstriction |
Sedation, dizziness, eight-hour driving restriction |
| Oral gepants |
Nurtec ODT, Ubrelvy |
No vasoconstriction and fewer functional restrictions |
Higher branded cost and payer management |
| Nasal gepants |
Zavzpret |
Rapid non-oral administration |
Newer product with limited long-term market history |
| Preventive CGRP products |
Qulipta, Emgality, Ajovy, Aimovig |
Preventive treatment |
Not substitutes for all acute-treatment use |
The principal commercial threat is from gepants. Gepants preserve the cardiovascular differentiation of Reyvow without the same driving restriction. Their adoption has reduced the size of the patient segment for which Reyvow has a compelling value proposition.
What is the financial trajectory of Reyvow?
Lilly does not report Reyvow as a separate revenue line in its annual reports. The product is grouped into broader categories or omitted from individually disclosed product sales because its revenue is below Lilly’s reporting threshold for major products [3].
| Period |
Commercial development |
Financial interpretation |
| 2019 |
FDA approval |
No meaningful commercial revenue before approval |
| 2020 |
U.S. launch during pandemic conditions |
Initial uptake was impaired by reduced office visits and disrupted prescribing |
| 2021 |
Wider availability and payer access |
Product remained a niche acute-migraine therapy |
| 2022-2023 |
Competition intensified from Nurtec, Ubrelvy, and other CGRP products |
No separately reported revenue indicates limited materiality to Lilly |
| 2024 onward |
NCE exclusivity expired; patent-based protection became more important |
Generic and authorized-generic risk increased over time |
Why are Reyvow sales not separately disclosed?
Lilly’s public reporting focuses on products that materially affect consolidated revenue. Its principal growth drivers have been Mounjaro, Trulicity, Verzenio, Taltz, Jardiance, Zepbound, and other high-revenue products. Reyvow has not been reported as a standalone major product in the same manner.
This prevents a reliable audited calculation of:
- Annual Reyvow net sales
- Prescription growth
- Average selling price
- Gross-to-net deductions
- U.S. versus international revenue
- Product-level operating margin
- Lilly’s current return on the CoLucid acquisition
The absence of standalone reporting is itself a market signal. Reyvow has not reached the commercial scale required for Lilly to identify it separately in investor disclosures.
How did the CoLucid acquisition affect lasmiditan’s economics?
Lilly acquired CoLucid Pharmaceuticals in 2017 for approximately $960 million. The transaction gave Lilly control of lasmiditan and the company’s migraine development platform [4].
The acquisition occurred before approval and shifted development, regulatory, manufacturing, and launch risk to Lilly. The commercial return has been pressured by:
- A narrow differentiation against gepants.
- A restrictive post-dose driving warning.
- Launch timing during the pandemic.
- Established generic triptan competition.
- Payer preference for lower-cost acute migraine therapies.
- The rapid expansion of the CGRP product class.
The transaction remains strategically important because it gave Lilly an entry into migraine without the vasoconstrictive profile of triptans. On disclosed financial evidence, however, Reyvow has not developed into a major revenue asset.
When does lasmiditan lose exclusivity?
Lasmiditan’s five-year U.S. new chemical entity exclusivity began with FDA approval on Oct. 11, 2019 and expired in October 2024. NCE exclusivity prevents the FDA from accepting certain abbreviated new drug applications, or ANDAs, for the same active moiety during the exclusivity period. It does not prevent patent challenges during the relevant patent term.
Patent protection may continue after NCE exclusivity. The commercial entry date therefore depends on the expiration, validity, and enforceability of listed patents, as well as any Paragraph IV litigation or settlement.
| Exclusivity layer |
Approximate timing |
Commercial effect |
| FDA approval |
Oct. 11, 2019 |
Market entry authorization |
| Five-year NCE exclusivity |
Through October 2024 |
Delayed ANDA filing for certain generic applicants |
| Pediatric extension |
No publicly established extension identified in the core approval record |
Would add six months only if awarded |
| Orange Book patents |
Potentially later than 2024 |
May block or delay approval or launch |
| Regulatory exclusivity outside the U.S. |
Jurisdiction-specific |
Depends on local rules and filings |
What patents protect lasmiditan succinate?
The lasmiditan estate includes composition-of-matter, pharmaceutical-composition, polymorph, and method-of-use disclosures. Public patent records associated with lasmiditan and the Reyvow program include U.S. Patent Nos. 9,278,096 and 10,583,110, among other family members and related applications.
| Patent category |
Protected subject matter |
Commercial relevance |
| Composition of matter |
Lasmiditan chemical structures and salts |
Usually the strongest barrier if valid and enforceable |
| Pharmaceutical composition |
Tablets, excipients, and dosage forms |
Can block specific formulations but may be designed around |
| Solid-state or salt forms |
Lasmiditan succinate and related forms |
May limit manufacturing routes and product composition |
| Method of use |
Acute treatment of migraine and related clinical uses |
Relevant to skinny-label generic strategies |
| Manufacturing processes |
Preparation and purification of lasmiditan |
Can increase supply-chain and process-development costs |
The most valuable protection is the earliest valid composition patent. Formulation and method-of-use patents can delay entry or complicate labeling, but they generally provide weaker protection than a broad, enforceable composition claim.
What is the Orange Book status of Reyvow?
The Orange Book determines which patents a generic applicant must address in an ANDA. Reyvow’s commercial exposure depends on the patents currently listed for the approved product, their expiration dates, and whether the FDA accepts later-listed patents.
A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. Lilly could respond with patent litigation, generally triggering a 30-month stay of final ANDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court developments [5].
The absence of a separately reported litigation event does not eliminate generic risk. A generic applicant can file after NCE exclusivity ends, depending on the applicable patent certifications and filing strategy.
Which companies are challenging or competing with lasmiditan?
The competitive field has two distinct groups: generic acute-migraine products and branded non-vasoconstrictive products.
Established generic competitors
Generic sumatriptan, rizatriptan, naratriptan, zolmitriptan, eletriptan, and almotriptan compete primarily on price and physician familiarity. Their limitations include cardiovascular precautions and incomplete response in some patients.
Branded CGRP competitors
| Product |
Company |
Position relative to Reyvow |
| Nurtec ODT |
Pfizer, formerly Biohaven |
Acute and preventive use; orally disintegrating tablet |
| Ubrelvy |
AbbVie |
Acute treatment; direct branded alternative |
| Zavzpret |
Pfizer |
Nasal acute-treatment option |
| Qulipta |
AbbVie |
Preventive treatment, with indirect effect on acute-treatment demand |
| Emgality |
Lilly |
Preventive migraine product within Lilly’s portfolio |
Nurtec and Ubrelvy have the strongest direct commercial overlap. They offer non-vasoconstrictive migraine treatment without Reyvow’s eight-hour driving restriction. Reyvow retains potential use in patients who fail or cannot access gepants, but its positioning is narrower.
What is the generic entry risk for lasmiditan?
Generic entry risk is moderate to high after the end of NCE exclusivity, although the timing depends on patent litigation and the scope of Orange Book claims.
Near-term entry scenario
A generic applicant may seek approval for lasmiditan tablets using an ANDA. The likely product would target the same active ingredient and dosage forms, initially using a label that avoids patented methods of use if legally feasible.
Launch scenarios
| Scenario |
Timing |
Market impact |
| No successful Paragraph IV challenge |
After relevant patent expiration |
Entry follows ordinary patent timetable |
| Paragraph IV filing with litigation |
Potentially delayed by litigation and 30-month stay |
Entry may occur through settlement or court ruling |
| At-risk launch |
Before final patent resolution |
High damages exposure if Lilly prevails |
| Authorized generic |
Controlled by Lilly or a partner |
Could reduce independent generic economics |
| Skinny-label launch |
Generic omits protected use language |
Preserves access for unpatented uses but may narrow uptake |
Generic erosion would likely be rapid because acute migraine patients and payers are price-sensitive, and the product has not established the level of brand loyalty seen with high-revenue specialty medicines.
How strong is the lasmiditan patent estate?
The patent estate has commercial value but does not have the strength of a broad, long-lived composition patent protecting a major chronic therapy.
Strengths
- A novel mechanism distinct from triptans.
- Composition and salt-form protection.
- FDA approval for a specific migraine indication.
- Manufacturing and formulation know-how held by Lilly or its suppliers.
- Potential Orange Book leverage after NCE exclusivity.
Weaknesses
- Small-molecule patents are vulnerable to Paragraph IV invalidity challenges.
- Gepants reduce the commercial value of blocking generic entry.
- A method-of-use-only barrier may permit a skinny-label strategy.
- The product’s clinical restrictions reduce the economic upside of extended exclusivity.
- Low reported revenue limits the damages base in patent litigation.
The estate is strategically relevant for preserving residual branded sales, but the underlying product economics are less attractive than those of Lilly’s metabolic, oncology, and immunology franchises.
What manufacturing and IP barriers affect lasmiditan?
Lasmiditan is an orally administered small molecule, so it does not have the cell-line, biologic comparability, or cold-chain barriers associated with monoclonal antibodies. Generic manufacturers face conventional small-molecule requirements:
- Active pharmaceutical ingredient synthesis
- Control of impurities and stereochemical quality
- Salt-form and solid-state characterization
- Tablet dissolution and bioequivalence
- Stability data
- Commercial-scale supply qualification
- Patent clearance for composition, formulation, and use claims
These barriers are meaningful but manageable for established generic manufacturers. They are unlikely to support durable premium pricing once multiple ANDA products enter.
What is the likely revenue trajectory for lasmiditan?
The likely trajectory is a niche branded product followed by erosion after generic availability. The product lacks the characteristics associated with major pharmaceutical franchises: broad preventive use, high chronic-treatment frequency, strong pricing power, or a large underpenetrated patient population.
Lilly’s financial exposure has three components:
- Residual Reyvow product revenue.
- Royalties, licensing, or acquisition-related return on the CoLucid assets.
- Cannibalization or portfolio interaction with Lilly’s Emgality business.
The third factor is limited because Emgality is preventive, while Reyvow is for acute attacks. The larger strategic issue is that Lilly participates in both a preventive CGRP market and a weaker acute ditan segment.
How does Reyvow compare with Nurtec and Ubrelvy?
| Factor |
Reyvow |
Nurtec ODT |
Ubrelvy |
| Mechanism |
5-HT1F agonist |
CGRP antagonist |
CGRP antagonist |
| Acute indication |
Yes |
Yes |
Yes |
| Preventive indication |
No |
Yes |
No |
| Vasoconstriction |
No |
No |
No |
| Driving restriction |
Eight hours |
No comparable label restriction |
No comparable label restriction |
| Dosage form |
Oral tablet |
Orally disintegrating tablet |
Oral tablet |
| Commercial positioning |
Alternative for selected patients |
Acute and preventive platform |
Branded acute-treatment competitor |
| Main risk to uptake |
Sedation and functional impairment |
Price and payer restrictions |
Price and payer restrictions |
Reyvow’s strongest clinical differentiation is its lack of vasoconstriction. Its strongest commercial disadvantage is that patients may be unable to drive, work, or operate machinery for eight hours after use.
Key Takeaways
- Reyvow is FDA-approved lasmiditan succinate for acute migraine treatment in adults.
- Lilly launched the product in February 2020 after acquiring CoLucid for approximately $960 million.
- Lilly does not disclose Reyvow revenue separately, indicating that sales are not material to its reported product portfolio.
- The five-year NCE exclusivity period ended in October 2024.
- Patent protection, Orange Book listings, and Paragraph IV litigation determine the practical generic-entry date.
- Gepants, especially Nurtec ODT and Ubrelvy, are the primary branded competitive threat.
- Generic erosion is likely to be substantial if ANDA approval occurs without a settlement that materially delays entry.
- The product’s eight-hour driving restriction is a major commercial limitation.
- Lasmiditan has a meaningful small-molecule patent estate, but the economic value of prolonged exclusivity is limited by modest commercial scale and intense competition.
FAQs About Lasmiditan Succinate and Reyvow
Is lasmiditan a CGRP drug?
No. Lasmiditan is a selective 5-HT1F receptor agonist. It is classified as a ditan, while Nurtec, Ubrelvy, and Zavzpret are CGRP-pathway drugs.
Can generic manufacturers make lasmiditan after October 2024?
They may be able to pursue ANDA approval after NCE exclusivity ends, but listed patents can delay approval or launch. The timing depends on patent certifications, litigation, settlements, and court outcomes.
Why did Reyvow struggle commercially despite having no vasoconstrictive effect?
The product has a narrow use case, causes central nervous system adverse effects, and carries an eight-hour driving restriction. Gepants offer a similar cardiovascular advantage without the same functional limitation.
Did Lilly discontinue Reyvow?
Public financial reports do not establish a product discontinuation. Reyvow has remained associated with Lilly’s migraine portfolio, although the company does not disclose standalone revenue.
Does lasmiditan have biosimilar risk?
No. Lasmiditan is a chemically synthesized small molecule, not a biologic. Its competitive threat is from generic drugs approved through the ANDA pathway, not biosimilars.
References
- U.S. Food and Drug Administration. (2019). FDA approves new treatment for adults with migraine. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). Reyvow (lasmiditan) prescribing information. Eli Lilly and Company.
- Eli Lilly and Company. (2024). 2023 annual report.
- Eli Lilly and Company. (2017). Lilly to acquire CoLucid Pharmaceuticals. https://investor.lilly.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/ htm
